| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Multiple Sclerosis | 22 | 2020 | 209 | 3.860 |
Why?
|
| Borrelia | 11 | 2011 | 25 | 2.740 |
Why?
|
| Multiple Sclerosis, Chronic Progressive | 6 | 2019 | 14 | 2.500 |
Why?
|
| Relapsing Fever | 8 | 2008 | 16 | 1.990 |
Why?
|
| Optic Neuritis | 5 | 2019 | 11 | 1.920 |
Why?
|
| Brain | 12 | 2013 | 1492 | 1.690 |
Why?
|
| Muscular Dystrophy, Facioscapulohumeral | 5 | 2024 | 39 | 1.540 |
Why?
|
| Interleukin-10 | 6 | 2011 | 147 | 1.540 |
Why?
|
| Antibodies, Monoclonal | 5 | 2019 | 857 | 1.530 |
Why?
|
| Borrelia Infections | 5 | 2010 | 11 | 1.520 |
Why?
|
| Disability Evaluation | 10 | 2019 | 216 | 1.510 |
Why?
|
| Borrelia burgdorferi | 8 | 2016 | 68 | 1.360 |
Why?
|
| Multiple Sclerosis, Relapsing-Remitting | 5 | 2019 | 33 | 1.290 |
Why?
|
| Lyme Disease | 7 | 2016 | 105 | 1.280 |
Why?
|
| Lyme Neuroborreliosis | 5 | 2016 | 9 | 1.280 |
Why?
|
| Immunologic Factors | 7 | 2018 | 99 | 1.190 |
Why?
|
| Visual Acuity | 3 | 2019 | 118 | 1.140 |
Why?
|
| Disease Progression | 8 | 2022 | 1052 | 0.990 |
Why?
|
| Fragile X Syndrome | 2 | 2022 | 28 | 0.990 |
Why?
|
| Bacterial Outer Membrane Proteins | 3 | 2010 | 138 | 0.960 |
Why?
|
| Magnetic Resonance Imaging | 15 | 2022 | 2049 | 0.950 |
Why?
|
| Nerve Tissue Proteins | 3 | 2019 | 417 | 0.940 |
Why?
|
| Chemokine CXCL13 | 6 | 2011 | 8 | 0.930 |
Why?
|
| Walking | 6 | 2016 | 229 | 0.920 |
Why?
|
| Spirochaetales | 3 | 2010 | 4 | 0.770 |
Why?
|
| Lipoproteins | 3 | 2011 | 84 | 0.770 |
Why?
|
| Membrane Proteins | 3 | 2019 | 844 | 0.760 |
Why?
|
| Endothelium, Vascular | 3 | 2011 | 171 | 0.730 |
Why?
|
| Bacteremia | 3 | 2011 | 93 | 0.700 |
Why?
|
| Visually Impaired Persons | 1 | 2019 | 14 | 0.650 |
Why?
|
| Male | 41 | 2024 | 27776 | 0.650 |
Why?
|
| Female | 43 | 2024 | 31113 | 0.640 |
Why?
|
| Severity of Illness Index | 6 | 2018 | 1461 | 0.640 |
Why?
|
| Antigens, Bacterial | 2 | 2010 | 212 | 0.620 |
Why?
|
| Central Nervous System Bacterial Infections | 2 | 2010 | 3 | 0.610 |
Why?
|
| Muscle, Skeletal | 5 | 2022 | 678 | 0.610 |
Why?
|
| Chemokines, CXC | 4 | 2007 | 27 | 0.610 |
Why?
|
| Macaca mulatta | 6 | 2005 | 248 | 0.600 |
Why?
|
| Humans | 54 | 2024 | 59836 | 0.590 |
Why?
|
| Adult | 28 | 2024 | 15888 | 0.580 |
Why?
|
| Recovery of Function | 1 | 2019 | 264 | 0.570 |
Why?
|
| Middle Aged | 27 | 2024 | 16404 | 0.570 |
Why?
|
| Treatment Outcome | 9 | 2024 | 5207 | 0.540 |
Why?
|
| Antibodies, Monoclonal, Humanized | 3 | 2013 | 223 | 0.540 |
Why?
|
| Gadolinium DTPA | 3 | 2020 | 85 | 0.530 |
Why?
|
| Apoptosis | 4 | 2011 | 1040 | 0.530 |
Why?
|
| B-Lymphocytes | 4 | 2009 | 552 | 0.510 |
Why?
|
| Inflammation | 4 | 2017 | 1106 | 0.500 |
Why?
|
| Benchmarking | 1 | 2016 | 135 | 0.500 |
Why?
|
| Blood-Brain Barrier | 6 | 2017 | 81 | 0.490 |
Why?
|
| Double-Blind Method | 5 | 2024 | 679 | 0.490 |
Why?
|
| Exercise Test | 2 | 2013 | 236 | 0.490 |
Why?
|
| Glatiramer Acetate | 5 | 2016 | 6 | 0.480 |
Why?
|
| Mice | 16 | 2019 | 10309 | 0.440 |
Why?
|
| Animals | 23 | 2019 | 19725 | 0.430 |
Why?
|
| Oligodendroglia | 1 | 2013 | 35 | 0.430 |
Why?
|
| Interferon-beta | 5 | 2013 | 76 | 0.430 |
Why?
|
| Young Adult | 10 | 2019 | 4370 | 0.420 |
Why?
|
| Patient Outcome Assessment | 1 | 2013 | 55 | 0.420 |
Why?
|
| Central Nervous System Diseases | 1 | 2013 | 56 | 0.410 |
Why?
|
| Self Report | 1 | 2015 | 368 | 0.410 |
Why?
|
| Simvastatin | 1 | 2012 | 28 | 0.400 |
Why?
|
| Contrast Media | 4 | 2020 | 414 | 0.390 |
Why?
|
| Interferon beta-1b | 4 | 2016 | 5 | 0.390 |
Why?
|
| Mice, SCID | 6 | 2009 | 506 | 0.380 |
Why?
|
| Encephalitis | 1 | 2012 | 32 | 0.380 |
Why?
|
| Anti-Bacterial Agents | 2 | 2016 | 731 | 0.380 |
Why?
|
| Microcirculation | 2 | 2008 | 51 | 0.370 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2012 | 213 | 0.350 |
Why?
|
| Antibodies, Bacterial | 6 | 2008 | 193 | 0.350 |
Why?
|
| Spirochaetales Infections | 1 | 2010 | 1 | 0.340 |
Why?
|
| Longitudinal Studies | 7 | 2017 | 1234 | 0.340 |
Why?
|
| Time Factors | 9 | 2018 | 3593 | 0.340 |
Why?
|
| Acute Disease | 4 | 2019 | 659 | 0.330 |
Why?
|
| Adolescent | 9 | 2019 | 5941 | 0.320 |
Why?
|
| Image Processing, Computer-Assisted | 7 | 2020 | 638 | 0.320 |
Why?
|
| Natalizumab | 4 | 2018 | 11 | 0.310 |
Why?
|
| Neuropsychological Tests | 5 | 2014 | 353 | 0.300 |
Why?
|
| Evoked Potentials, Visual | 2 | 2018 | 13 | 0.300 |
Why?
|
| Neurons | 2 | 2013 | 861 | 0.300 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 6 | 2008 | 525 | 0.300 |
Why?
|
| Reproducibility of Results | 7 | 2022 | 1559 | 0.280 |
Why?
|
| Vestibular Diseases | 1 | 2007 | 9 | 0.280 |
Why?
|
| Cognition Disorders | 3 | 2014 | 219 | 0.280 |
Why?
|
| Myocarditis | 2 | 2005 | 61 | 0.280 |
Why?
|
| Cross-Sectional Studies | 3 | 2022 | 2491 | 0.270 |
Why?
|
| Gadolinium | 4 | 2017 | 102 | 0.270 |
Why?
|
| Peptides | 4 | 2012 | 546 | 0.260 |
Why?
|
| Root Canal Therapy | 2 | 2017 | 3 | 0.260 |
Why?
|
| Radiography, Dental, Digital | 2 | 2017 | 3 | 0.260 |
Why?
|
| Surveys and Questionnaires | 4 | 2019 | 2601 | 0.260 |
Why?
|
| T-Lymphocytes | 2 | 2007 | 968 | 0.240 |
Why?
|
| Cerebrovascular Circulation | 1 | 2006 | 171 | 0.240 |
Why?
|
| Disease Models, Animal | 4 | 2004 | 2079 | 0.240 |
Why?
|
| Cyclopropanes | 2 | 2024 | 41 | 0.240 |
Why?
|
| Cone-Beam Computed Tomography | 2 | 2017 | 71 | 0.240 |
Why?
|
| Borrelia burgdorferi Group | 1 | 2004 | 27 | 0.230 |
Why?
|
| Pyridines | 2 | 2024 | 98 | 0.230 |
Why?
|
| Mice, Knockout | 4 | 2011 | 1997 | 0.220 |
Why?
|
| Leukoencephalopathy, Progressive Multifocal | 2 | 2013 | 18 | 0.210 |
Why?
|
| Heart Diseases | 1 | 2005 | 204 | 0.210 |
Why?
|
| Cytokines | 2 | 2008 | 909 | 0.210 |
Why?
|
| Homeodomain Proteins | 2 | 2020 | 256 | 0.210 |
Why?
|
| Adipose Tissue | 2 | 2022 | 283 | 0.210 |
Why?
|
| Spinal Cord | 1 | 2004 | 197 | 0.210 |
Why?
|
| Hair Follicle | 1 | 2022 | 29 | 0.210 |
Why?
|
| Serotyping | 3 | 2007 | 50 | 0.200 |
Why?
|
| Polymerase Chain Reaction | 3 | 2009 | 498 | 0.200 |
Why?
|
| Fragile X Mental Retardation Protein | 1 | 2022 | 37 | 0.200 |
Why?
|
| Social Communication Disorder | 1 | 2022 | 2 | 0.200 |
Why?
|
| Quality of Life | 4 | 2019 | 1129 | 0.190 |
Why?
|
| Placebos | 2 | 2012 | 71 | 0.190 |
Why?
|
| Inflammation Mediators | 1 | 2002 | 169 | 0.190 |
Why?
|
| Cerebral Cortex | 2 | 2017 | 253 | 0.190 |
Why?
|
| RNA, Messenger | 2 | 2022 | 1470 | 0.190 |
Why?
|
| Cerebellar Nuclei | 1 | 2020 | 4 | 0.180 |
Why?
|
| Gray Matter | 1 | 2020 | 29 | 0.180 |
Why?
|
| Phenotype | 1 | 2004 | 1154 | 0.180 |
Why?
|
| Cluster Analysis | 2 | 2012 | 251 | 0.180 |
Why?
|
| Tooth Root | 2 | 2017 | 2 | 0.170 |
Why?
|
| Immunocompromised Host | 3 | 2006 | 95 | 0.170 |
Why?
|
| Chemokines | 2 | 2013 | 94 | 0.170 |
Why?
|
| Bites and Stings | 3 | 2004 | 11 | 0.170 |
Why?
|
| Electroencephalography | 2 | 2019 | 138 | 0.170 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2020 | 125 | 0.170 |
Why?
|
| White Matter | 2 | 2019 | 114 | 0.170 |
Why?
|
| Evoked Potentials, Somatosensory | 1 | 2019 | 8 | 0.170 |
Why?
|
| Evoked Potentials, Auditory | 1 | 2019 | 10 | 0.170 |
Why?
|
| DNA Primers | 2 | 2010 | 291 | 0.170 |
Why?
|
| Myocardium | 3 | 2006 | 263 | 0.170 |
Why?
|
| Retrospective Studies | 6 | 2020 | 6042 | 0.160 |
Why?
|
| Ixodes | 3 | 2004 | 31 | 0.160 |
Why?
|
| Pilot Projects | 1 | 2022 | 927 | 0.160 |
Why?
|
| Statistics, Nonparametric | 2 | 2012 | 207 | 0.160 |
Why?
|
| Sickness Impact Profile | 1 | 2019 | 46 | 0.160 |
Why?
|
| Encephalomyelitis, Autoimmune, Experimental | 1 | 2019 | 58 | 0.160 |
Why?
|
| Biomarkers | 2 | 2022 | 1205 | 0.160 |
Why?
|
| Immunosuppressive Agents | 2 | 2012 | 303 | 0.160 |
Why?
|
| Infusions, Intravenous | 1 | 2019 | 169 | 0.160 |
Why?
|
| Clinical Trials as Topic | 2 | 2013 | 442 | 0.160 |
Why?
|
| Retinal Ganglion Cells | 1 | 2018 | 27 | 0.160 |
Why?
|
| Optic Nerve | 1 | 2018 | 28 | 0.160 |
Why?
|
| Secondary Prevention | 1 | 2019 | 154 | 0.150 |
Why?
|
| Mice, Inbred C57BL | 4 | 2019 | 3207 | 0.150 |
Why?
|
| Antibodies | 2 | 2009 | 176 | 0.150 |
Why?
|
| Autism Spectrum Disorder | 1 | 2022 | 181 | 0.150 |
Why?
|
| Hand | 1 | 2018 | 66 | 0.150 |
Why?
|
| Penicillin G | 1 | 2016 | 5 | 0.140 |
Why?
|
| Cefotaxime | 1 | 2016 | 4 | 0.140 |
Why?
|
| Amoxicillin | 1 | 2016 | 7 | 0.140 |
Why?
|
| PubMed | 1 | 2017 | 17 | 0.140 |
Why?
|
| Ceftriaxone | 1 | 2016 | 19 | 0.140 |
Why?
|
| Doxycycline | 1 | 2016 | 41 | 0.140 |
Why?
|
| International Cooperation | 1 | 2017 | 81 | 0.140 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2008 | 449 | 0.130 |
Why?
|
| Tomography, Optical Coherence | 1 | 2018 | 207 | 0.130 |
Why?
|
| Predictive Value of Tests | 3 | 2013 | 1030 | 0.130 |
Why?
|
| Mice, Inbred BALB C | 2 | 2009 | 880 | 0.130 |
Why?
|
| Upper Extremity | 1 | 2016 | 49 | 0.130 |
Why?
|
| Myocytes, Cardiac | 2 | 2006 | 88 | 0.130 |
Why?
|
| Hypophosphatemia | 1 | 2015 | 6 | 0.120 |
Why?
|
| Psychometrics | 2 | 2014 | 357 | 0.120 |
Why?
|
| Activities of Daily Living | 2 | 2014 | 300 | 0.120 |
Why?
|
| DNA, Bacterial | 2 | 2006 | 260 | 0.120 |
Why?
|
| Demography | 1 | 2015 | 178 | 0.120 |
Why?
|
| Endothelial Growth Factors | 1 | 2014 | 21 | 0.120 |
Why?
|
| Synovial Membrane | 1 | 2014 | 19 | 0.120 |
Why?
|
| Brain Injuries | 1 | 2016 | 137 | 0.120 |
Why?
|
| RNA, Bacterial | 2 | 2004 | 70 | 0.110 |
Why?
|
| Aged | 6 | 2022 | 13464 | 0.110 |
Why?
|
| Immunohistochemistry | 3 | 2005 | 848 | 0.110 |
Why?
|
| Gait Disorders, Neurologic | 1 | 2013 | 18 | 0.110 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2007 | 291 | 0.110 |
Why?
|
| Heart | 2 | 2007 | 276 | 0.110 |
Why?
|
| Disabled Persons | 1 | 2016 | 205 | 0.110 |
Why?
|
| Autoantibodies | 1 | 2014 | 175 | 0.110 |
Why?
|
| Radiography, Bitewing | 1 | 2013 | 1 | 0.110 |
Why?
|
| Dental Pulp Cavity | 1 | 2013 | 2 | 0.110 |
Why?
|
| Interferon beta-1a | 1 | 2013 | 9 | 0.110 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2016 | 684 | 0.100 |
Why?
|
| Dexamethasone | 2 | 2004 | 196 | 0.100 |
Why?
|
| Employment | 1 | 2013 | 136 | 0.100 |
Why?
|
| Neuroimaging | 1 | 2013 | 131 | 0.100 |
Why?
|
| Follow-Up Studies | 3 | 2013 | 2341 | 0.100 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2004 | 161 | 0.100 |
Why?
|
| Cell Survival | 1 | 2013 | 557 | 0.090 |
Why?
|
| Cell Line | 3 | 2020 | 2015 | 0.090 |
Why?
|
| Remission Induction | 1 | 2011 | 138 | 0.090 |
Why?
|
| fas Receptor | 1 | 2011 | 54 | 0.090 |
Why?
|
| Caspase 3 | 1 | 2011 | 104 | 0.090 |
Why?
|
| Drug Administration Schedule | 2 | 2015 | 279 | 0.090 |
Why?
|
| Mice, Inbred Strains | 1 | 2010 | 182 | 0.090 |
Why?
|
| Drug Tolerance | 1 | 2009 | 28 | 0.080 |
Why?
|
| Neurologic Examination | 1 | 2009 | 51 | 0.080 |
Why?
|
| Molecular Conformation | 1 | 2009 | 133 | 0.080 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2010 | 141 | 0.080 |
Why?
|
| Observer Variation | 1 | 2009 | 201 | 0.080 |
Why?
|
| Tissue Distribution | 1 | 2009 | 285 | 0.080 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2008 | 43 | 0.080 |
Why?
|
| Prospective Studies | 2 | 2013 | 3110 | 0.080 |
Why?
|
| Structure-Activity Relationship | 1 | 2009 | 376 | 0.080 |
Why?
|
| Phylogeny | 1 | 2009 | 334 | 0.080 |
Why?
|
| Coloring Agents | 1 | 2008 | 54 | 0.080 |
Why?
|
| Base Sequence | 1 | 2010 | 1311 | 0.070 |
Why?
|
| Interferon Type I | 1 | 2009 | 168 | 0.070 |
Why?
|
| Cognition | 1 | 2012 | 466 | 0.070 |
Why?
|
| Sensitivity and Specificity | 1 | 2010 | 1098 | 0.070 |
Why?
|
| Aging | 1 | 2013 | 731 | 0.070 |
Why?
|
| Recombinant Proteins | 1 | 2009 | 696 | 0.070 |
Why?
|
| Killer Cells, Natural | 1 | 2008 | 214 | 0.070 |
Why?
|
| Spleen | 1 | 2008 | 486 | 0.070 |
Why?
|
| Interleukin-6 | 1 | 2008 | 309 | 0.070 |
Why?
|
| Arthritis | 1 | 2007 | 50 | 0.070 |
Why?
|
| Primates | 1 | 2006 | 42 | 0.070 |
Why?
|
| Hemorrhage | 1 | 2008 | 269 | 0.070 |
Why?
|
| Immunoglobulins | 1 | 2006 | 76 | 0.070 |
Why?
|
| Antibody Formation | 1 | 2006 | 111 | 0.070 |
Why?
|
| Complement Activation | 1 | 2006 | 53 | 0.070 |
Why?
|
| Interferon-gamma | 1 | 2008 | 548 | 0.070 |
Why?
|
| Survival Rate | 1 | 2008 | 790 | 0.060 |
Why?
|
| Cells, Cultured | 1 | 2010 | 2099 | 0.060 |
Why?
|
| Gene Expression Regulation, Bacterial | 1 | 2007 | 149 | 0.060 |
Why?
|
| Down-Regulation | 1 | 2007 | 305 | 0.060 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2008 | 584 | 0.060 |
Why?
|
| Caspases | 1 | 2006 | 164 | 0.060 |
Why?
|
| Germinal Center | 1 | 2005 | 37 | 0.060 |
Why?
|
| Nervous System | 1 | 2005 | 69 | 0.060 |
Why?
|
| Safety | 1 | 2005 | 141 | 0.060 |
Why?
|
| Brain Infarction | 1 | 2004 | 19 | 0.060 |
Why?
|
| Mice, Inbred C3H | 1 | 2004 | 174 | 0.060 |
Why?
|
| Complement C1q | 1 | 2004 | 8 | 0.060 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2005 | 238 | 0.060 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 2004 | 36 | 0.060 |
Why?
|
| Immunoenzyme Techniques | 1 | 2004 | 104 | 0.060 |
Why?
|
| Aorta | 1 | 2004 | 106 | 0.060 |
Why?
|
| Adjuvants, Immunologic | 1 | 2005 | 228 | 0.060 |
Why?
|
| Needles | 1 | 2003 | 64 | 0.050 |
Why?
|
| Signal Transduction | 1 | 2013 | 2891 | 0.050 |
Why?
|
| HIV Infections | 1 | 2010 | 927 | 0.050 |
Why?
|
| Genotype | 1 | 2004 | 641 | 0.050 |
Why?
|
| DNA-Binding Proteins | 1 | 2008 | 1136 | 0.050 |
Why?
|
| Multicenter Studies as Topic | 1 | 2022 | 120 | 0.050 |
Why?
|
| Research Design | 2 | 2018 | 569 | 0.050 |
Why?
|
| Child | 3 | 2022 | 4325 | 0.050 |
Why?
|
| Area Under Curve | 1 | 2021 | 125 | 0.050 |
Why?
|
| Immunity, Innate | 1 | 2007 | 768 | 0.050 |
Why?
|
| Macrophages | 1 | 2006 | 1011 | 0.040 |
Why?
|
| Muscle Cells | 1 | 2020 | 27 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2022 | 523 | 0.040 |
Why?
|
| Administration, Oral | 1 | 2021 | 345 | 0.040 |
Why?
|
| Linear Models | 1 | 2020 | 423 | 0.040 |
Why?
|
| Myelin Sheath | 1 | 2019 | 36 | 0.040 |
Why?
|
| Cohort Studies | 2 | 2017 | 2461 | 0.040 |
Why?
|
| Chronic Disease | 1 | 2002 | 741 | 0.040 |
Why?
|
| Gene Expression Profiling | 1 | 2002 | 707 | 0.040 |
Why?
|
| Cell Death | 1 | 2020 | 272 | 0.040 |
Why?
|
| Nerve Fibers | 1 | 2018 | 29 | 0.040 |
Why?
|
| Visual Perception | 1 | 2018 | 41 | 0.040 |
Why?
|
| Visual Fields | 1 | 2018 | 43 | 0.040 |
Why?
|
| Photic Stimulation | 1 | 2018 | 90 | 0.040 |
Why?
|
| Software | 1 | 2020 | 373 | 0.040 |
Why?
|
| Communication | 1 | 2022 | 556 | 0.030 |
Why?
|
| Child, Preschool | 1 | 2022 | 1844 | 0.030 |
Why?
|
| Image Enhancement | 1 | 2017 | 190 | 0.030 |
Why?
|
| World Health Organization | 1 | 2014 | 30 | 0.030 |
Why?
|
| Phosphates | 1 | 2015 | 91 | 0.030 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2016 | 272 | 0.030 |
Why?
|
| Prognosis | 1 | 2018 | 1584 | 0.030 |
Why?
|
| Space Perception | 1 | 2014 | 19 | 0.030 |
Why?
|
| Acoustic Stimulation | 1 | 2014 | 50 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2014 | 189 | 0.030 |
Why?
|
| Demyelinating Diseases | 1 | 2013 | 15 | 0.030 |
Why?
|
| Immune Reconstitution Inflammatory Syndrome | 1 | 2013 | 14 | 0.030 |
Why?
|
| Calcium Sulfate | 1 | 2013 | 1 | 0.030 |
Why?
|
| Dental Restoration, Temporary | 1 | 2013 | 1 | 0.030 |
Why?
|
| Periapical Diseases | 1 | 2013 | 1 | 0.030 |
Why?
|
| Root Canal Irrigants | 1 | 2013 | 1 | 0.030 |
Why?
|
| Root Canal Obturation | 1 | 2013 | 1 | 0.030 |
Why?
|
| Zinc Oxide-Eugenol Cement | 1 | 2013 | 1 | 0.030 |
Why?
|
| Rubber Dams | 1 | 2013 | 1 | 0.030 |
Why?
|
| Root Canal Preparation | 1 | 2013 | 1 | 0.030 |
Why?
|
| Zinc Sulfate | 1 | 2013 | 1 | 0.030 |
Why?
|
| Root Canal Filling Materials | 1 | 2013 | 2 | 0.030 |
Why?
|
| Dental Restoration, Permanent | 1 | 2013 | 2 | 0.030 |
Why?
|
| Methylmethacrylates | 1 | 2013 | 2 | 0.030 |
Why?
|
| Anatomic Variation | 1 | 2013 | 6 | 0.030 |
Why?
|
| Sodium Hypochlorite | 1 | 2013 | 12 | 0.030 |
Why?
|
| Gene Expression Regulation | 1 | 2020 | 1539 | 0.030 |
Why?
|
| Early Diagnosis | 1 | 2013 | 90 | 0.030 |
Why?
|
| Mobility Limitation | 1 | 2013 | 49 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2015 | 798 | 0.030 |
Why?
|
| Statistics as Topic | 1 | 2013 | 147 | 0.030 |
Why?
|
| Memory | 1 | 2014 | 118 | 0.030 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 2012 | 24 | 0.030 |
Why?
|
| Microscopy | 1 | 2013 | 88 | 0.030 |
Why?
|
| New York | 1 | 2012 | 137 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2013 | 909 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2012 | 577 | 0.020 |
Why?
|
| Single-Blind Method | 1 | 2009 | 135 | 0.020 |
Why?
|
| Monitoring, Physiologic | 1 | 2009 | 150 | 0.020 |
Why?
|
| Necrosis | 1 | 2004 | 140 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 2005 | 638 | 0.010 |
Why?
|
| Immunoglobulin G | 1 | 2005 | 453 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2004 | 5149 | 0.010 |
Why?
|
| Risk Factors | 1 | 2004 | 5040 | 0.010 |
Why?
|